2024 ESC Guidelines for the management of chronic coronary syndromes
The 2024 ESC Guidelines on chronic coronary syndromes (CCS) span diagnosis and risk stratification, anti-anginal and event-prevention therapy, and revascularisation. This page surfaces the landmark trials from our register that the guideline cites — grouped by theme — so you can jump from a recommendation to the evidence that underpins it.
This guideline cites 38 of the 199 landmark trials in our Cardiology register.
Diagnosis & imaging1
- 2018SCOT-HEARTCardiology · Coronary · CT coronary angiographyScottish COmputed Tomography of the HEART trial
Revascularisation vs. medical therapy13
- 2023ORBITA-2Cardiology · Coronary · RevascularisationA Placebo-Controlled Trial of PCI for Stable Angina
- 2022FAME 3Cardiology · Coronary · FFR-guided PCIFractional flow reserve versus Angiography for Multivessel Evaluation 3
- 2022REVIVED-BCIS2Cardiology · Coronary · PCI vs OMTREVascularization for Ischemic VEntricular Dysfunction — British Cardiovascular Intervention Society-2
- 2020ISCHEMIACardiology · Coronary · RevascularisationInternational Study of Comparative Health Effectiveness with Medical and Invasive Approaches
- 2018ORBITACardiology · Coronary · RevascularisationObjective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty
- 2016EXCELCardiology · Coronary · left main PCIEvaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
- 2016NOBLECardiology · Coronary · left main PCINordic-Baltic-British Left Main Revascularisation Study
- 2016STICHCardiology · HF · CABGSurgical Treatment for Ischemic Heart Failure — Extension Study (STICHES, 10-year follow-up)
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIFractional flow reserve versus Angiography for Multivessel Evaluation 2
- 2012FREEDOMCardiology · Coronary · PCI vs CABGFuture REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease
- 2009FAMECardiology · Coronary · RevascularisationFractional Flow Reserve versus Angiography for Multivessel Evaluation
- 2009SYNTAXCardiology · Coronary · PCI vs CABGSYNergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery
- 2007COURAGECardiology · Coronary · RevascularisationClinical Outcomes Utilising Revascularisation and Aggressive Drug Evaluation
Antithrombotic therapy4
- 2019AUGUSTUSCardiology · Thrombosis · AF + PCIAntithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisCardiovascular Outcomes for People Using Anticoagulation Strategies
- 2013WOESTCardiology · Thrombosis · AF + PCIWhat is the Optimal antiplatelet and anticoagulant therapy in patients with OAC and coronary StenTing
- 2009PLATOCardiology · Coronary · AntiplateletsPlatelet Inhibition and Patient Outcomes
Lipid-lowering & anti-inflammatory therapy5
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLBempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
- 2017FOURIERCardiology · Lipids · PCSK9iFurther Cardiovascular Outcomes Research with PCSK9 Inhibition
- 2017CANTOSCardiology · Lipids · Anti-inflammatoryCanakinumab Anti-inflammatory Thrombosis Outcomes Study
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLImproved Reduction of Outcomes: Vytorin Efficacy International Trial
Cardiometabolic therapy3
- 2023SELECTCardiology · Cardiometabolic · GLP-1 RASemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- 2015EMPA-REG OUTCOMECardiology · Cardiometabolic · SGLT2 inhibitorsEmpagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes
Prevention & RAAS blockade1
- 2000HOPECardiology · Coronary · ACE inhibitorHeart Outcomes Prevention Evaluation
Heart failure & LV dysfunction7
- 2022DELIVERCardiology · HF · SGLT2 inhibitorsDapagliflozin Evaluation to Improve the Lives of Patients with Preserved-EF Heart Failure
- 2021EMPEROR-PreservedCardiology · HF · SGLT2 inhibitorsEmpagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved EF
- 2020EMPEROR-ReducedCardiology · HF · SGLT2 inhibitorsEmpagliflozin Outcome Trial in Chronic Heart Failure With Reduced EF
- 2019DAPA-HFCardiology · HF · SGLT2 inhibitorsDapagliflozin and Prevention of Adverse outcomes in Heart Failure
- 2014PARADIGM-HFCardiology · HF · ARNIProspective comparison of ARNI with ACEI to Determine Impact on Global Mortality
- 2003CHARMCardiology · HF · ARBCandesartan in Heart failure: Assessment of Reduction in Mortality and morbidity — Overall Programme
- 1991SOLVDCardiology · HF · ACE inhibitorStudies of Left Ventricular Dysfunction — Treatment Trial
Device therapy & sudden death3
Structural comorbidity1
- 2023TRILUMINATECardiology · Structural · TricuspidTranscatheter Repair for Patients with Tricuspid Regurgitation